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A MULTIDISCIPLINARY INITIATIVE TO REDUCE VANCOMYCIN-RESIS-
TANT ENTEROCOCCUS (VRE) INCIDENCE ON A PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT UNIT
Gainer, L.1, Johnson, B.1, Nickley, J.1, Potter-Bynoe, G.2, Scanlon, P.2,
Lehmann, L.3 1Children’s Hospital Boston, Boston, MA; 2Children’s Hos-
pital Boston, Boston, MA; 3Dana-Farber Cancer Institute, Boston, MA
Hematopoetic stem cell transplant (HSCT) patients are at risk for
bacteremia caused by resistant organisms, such as vancomycin-resis-
tant enterococcus (VRE), due to repeated courses of antimicrobial
therapy and neutropenia. Early VRE bacteremia during HSCT has
been associatedwith highmorbidity andmortality. Thus, implemen-
tation and monitoring of recommended infection prevention mea-
sures is critical. Recommendations include: judicious use of
antibiotics, health care worker education, hand hygiene compliance,
Standard and Contact precautions adherence, and surveillance for
VRE, which in our unit includes active surveillance cultures (ASC).
In the spring of 2008, an increase in VRE incidence prompted the
formation of amultidisciplinary team comprised ofHSCT, Infection
Control, and Environmental Services (ESD) personnel. Microbiol-
ogy records for our 13-bed pediatric HSCTunit revealed that the in-
cidence of VRE had increased from 1.8/1000 patient days in 2007 to
3.8/1000 patient days during the first 6 months of 2008. Our inves-
tigation revealed gaps in our ASC protocol. Admission ASC was of-
ten overlooked, making it difficult to determine whether the VRE
was acquired on our unit. To improve case finding, we emphasized
collecting ASC on admission with Infection Control performing
random audits to assess compliance. Our hospital protocol for dis-
continuing Contact precautions for patients with VRE is based on
serial rescreening. However, our investigation revealed that the pro-
tocol may not be applicable in HSCT patients prior to engraftment.
Therefore, HSCT patients with VRE must now be at least 100 days
post transplant before evaluation to discontinue Contact precautions
can be initiated. To address the potential role of the environment in
VRE transmission, we reviewed existing daily and discharge proce-
dures and enhanced the cleaning procedures of all patient rooms
and common areas. In lieu of restricting the use of common areas
by families, education on the importance of hand hygiene when en-
tering and leaving their child’s room was emphasized. As an added
measure, our unit requires HSCT patients to remain in their rooms
for the first 7 days of their admission to the unit. The use of preemp-
tive Contact precautions pending ASC results has been implemented
as an additional prevention strategy. During the 3rd quarter of 2008,
VRE incidence decreased to 1.9/1000 patient days and improvement
in compliance with our ASC protocol was realized.425
LOW-DOSE AZACITIDINE (AZA) AS MAINTENENCE THERAPY AFTER
ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION (HSCT) IN
RELAPSED AML OR MDS: A NURSING PERSPECTIVE
Metoyer, L.J., Champlin, R., Gulbis, A., da Silva, L., de Lima, M.,
Giralt, S. University of Texas at MD Anderson Cancer Center, Houston,
TX
Supportive care for allogeneic HSCT in patients with AML or
MDShas improved significantly over timewhich has resulted in a de-
crease in the rate of non relapse mortality. However, the incidence of
relapse has not been greatly impacted. Disease status at the time of
transplant is the most valid predictor for relapse, and recurrence re-
mains a major cause of treatment failure in this patient population.
Modification of treatment preparative regimens has not proven to
be beneficial. Despite the investigation of multiple chemotherapy/
radiation therapy combinations, reduction in the risk of relapse with-
out an increase of non relapsemortality has not been achieved for pa-
tients transplanted with relapsed and or refractory disease.
Azacitidine (AZA) is approved by the FDA for the treatment of
MDS at doses that are unlikely to be tolerated post HSCT due to
mylesuppression. In patients with relapsed AML or MDS at the
time of transplant, maintenance therapy with low dose AZA after
HSCT may provide adjuvant support for the allogeneic graft versus
leukemia affect, potentially decreasing recurrence rates. There is
limited experience with administration of chemotherapy and/or
the use of AZA in this setting. A dose and schedule finding study
for the use of AZA as maintenance therapy is being performed atMDAndersonCancer Center. AZA is given for four cycles in a doses
ranging from 8–32 mg/m2 starting on day1 42 subcutaneously daily
for 5 days every 28 days for a total of 4 cycles. Conditioning regimen
included gemtuzumab ozogamicin 2 mg/m2, fludarabine 120 mg/m2,
and melphalan140 mg/m2. Graft versus host disease (GVHD)
prophylaxis was tacrolimus/mini-methotraxate, with rabbit anti-
thymocyte globulin (rATG) in unrelated donor HSCT. Criteria for
patients to receive AZA include complete remission on day1 30 after
transplant with donor chimerism, no grade III/IV GVHD, platelets
greater than 10,000 and ANC. 500/ mm3. In all, 88 cycles were de-
livered at 8 (n5 7), 16 (n5 5), 24 (n5 21) and 32mg/m2 (n5 9). AZA
possible associated toxicities include grade I/II or III thrombocytope-
nia, grade I nausea, grade II fatigue, grade III transaminase elevation,
conjunctival erythema, prurititus, confusion, retinal hemorrhage,
grade II creatinine elevation, oral ulcers, papilledema and pulmonary
hemorrhage, and infections. Nursing issues related to drug adminis-
tration and monitoring will be discussed in further detail.426
PROPHYLACTIC CIPROFLOXACIN IN BK VIRUS POSITIVE ALLOGENEIC
STEM CELL TRANSPLANT RECIPIENTS AT KOSAIR CHILDREN’S HOSPITAL
Hente, M.L.1, Grant, J.O.1, Bowman, T.1, Wilkerson, R.1, Waldron, R.1,
Cheerva, A.C.2 1Kosair Children’’s Hosptial, Louisville, KY; 2University
of Louisville, Louisville, KY
Polyoma BK virus (BKV) is associated with hemorrhagic cystitis
(HC) in allogenenic stem cell transplants. This virus was first re-
ported in 1971, but testing for it has been available only for approx-
imately the past 5 years. It is very prevalent in human subjects (up to
80% of adults are infected), but only causes clinical issues in immu-
nocompromised patients possibly leading to hepatitis, retinitis,
pneumonitis and encephalopathy. Recent reports have suggested
that Ciprofloxacin (Cipro) can decrease urinary BKV reactivation af-
ter HSCT. Therefore, this institution began utilizing prophylactic
Cipro to attempt to reduce viral load and therefore, also the inci-
dence of HC. In this institution, Cipro was given prophylactically
to 4 BKV positive patients, of whom, 3 diagnoses were acute myeloid
leukemia and 1 diagnosis was acute lymphocytic leukemia. Two pa-
tients had BKV detected by PCR in their urine and no symptoms of
HC and 2 who were positive had moderate to severe clinical symp-
toms of HC. Standard preparative regimes were utilized with diverse
donor graft sources. All patients started with intravenous dosing of
Cipro, 1 with high dose due to severe HC and 3 with prophylaxis
dose. They were all switched to oral dosing when tolerated. All pa-
tients tolerated Cipro well and there were no side effects due to
this medication. Quantitative BKV PCR’s were done on urine at
least weekly and on serum if the patient became febrile. Urinalyses
were done frequently throughout the treatment period. Only 1 pa-
tient had positive serumPCR’s, whichwere noted prior to institution
of Cipro. The PCR continued to rise even with institution of Cipro
and never became negative. This patient succumbed to multiple in-
fections and GVHD (1145) after being on Cipro for 7 weeks. The
other patients (150, 1124 and1153) remain alive, 2 free of clinical
symptoms and off Cipro (given 17-50 and 130–50), and 1 remains
in the hospital on Cipro (150) and negative for clinical symptoms.
After initiation of Cipro, the BKV urinary viral loads decreased in
2 patients and increased in 2 patients. Two patients had HC before
starting Cipro (1 continued to increase viral load while the other de-
creased) and 2 did not have HC (1 continued to increase viral load
while the other did not). In conclusion, 50% of the patients in our
institution remained symptom free and a larger study should be
done to determine if Cipro is effective in decreasing BK urinary viral
loads and HC in stem cell transplant patients.427
A MULTIDISCIPLINARY CLINICAL PROCESS TO ADDRESS THE STEM CELL
TRANSPLANTATATION PATIENT WITH SPECIAL NEEDS
Tomczak, N., Davis, L., Neumann, J., Johnston, P., Sorenson, S. MD
Anderson Cancer Center, Houston, TX
Background: Undergoing a Stem Cell Transplantation (SCT)
can be a very complex process for patients, their caregivers, and
healthcare workers. When additional factors are included: a history
